References
- Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30(2):373–393.
- Luzzatto L, Arese P. Favism and glucose-6-phosphate dehydrogenase deficiency. N Engl J Med. 2018;378(1):60–71.
- Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297–316.
- Maisels MJ, Bhutani VK, Bogen D, et al. Hyperbilirubinemia in the Newborn Infant > or =35 weeks’ gestation: an update with clarifications. Pediatrics. 2009;124(4):1193–1198.
- Bhutani VK, Zipursky A, Blencowe H, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res. 2013;74(S1):86–100.
- Liu H, Liu W, Tang X, et al. Association between G6PD deficiency and hyperbilirubinemia in neonates: a meta-analysis. Pediatr Hematol Oncol. 2015;32(2):92–98.
- Duparc S, Beutler E. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77(4):779–789.
- Chinevere TD, Murray CK, Grant E, et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army Personnel. Mil Med. 2006;171(9):905–907.
- WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67:601–611.
- Nock ML, Johnson EM, Krugman RR, et al. Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States. J Perinatol. 2011;31(2):112–117.
- Johnson L, Bhutani VK, Karp K, et al. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol. 2009;29(S1):S25–S45.
- Watchko JF. Screening for glucose-6-phosphate dehydrogenase deficiency in newborns-practical considerations. J Pediatr. 2012;161(2):179–180.
- Bhutani VK, Kaplan M, Glader B, et al. Point-of-care quantitative measure of glucose-6-phosphate dehydrogenase enzyme deficiency. Pediatrics. 2015;136(5):e1268–e1275.
- Wong RJ, Montiel C, Kunda M, et al. A novel point-of-care device for measuring glucose-6-phosphate dehydrogenase enzyme deficiency. Semin Perinatol. 2021;45(1):151356.
- Bahr TM, Christensen RD, Agarwal AM, et al. The Neonatal Acute Bilirubin Encephalopathy Registry (NABER): background, aims, and protocol. Neonatology. 2019;115(3):242–246.
- Brooks JC, Fisher-Owens SA, Wu YW, et al. Evidence suggests there was not a “resurgence” of Kernicterus in the 1990s. Pediatrics. 2011;127(4):672–679.
- NVSS – National Vital Statistics System Homepage. 2020; [cited 2020 Feb 3]. Available from: https://www.cdc.gov/nchs/nvss/index.htm.
- Weng Y-H, Chiu Y-W. Clinical characteristics of G6PD deficiency in infants with marked hyperbilirubinemia. J Pediatr Hematol Oncol. 2010;32:11–14.
- Burke BL, Robbins JM, Bird TM, et al. Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988–2005. Pediatrics. 2009;123(2):524–532.
- Bhutani VK, Johnson L. Kernicterus in the 21st century: frequently asked questions. J Perinatol. 2009;29(S1):S20–S24.
- Kaplan M, Hammerman C. Neonatal screening for glucose-6-phosphate dehydrogenase deficiency: biochemical versus genetic technologies. Semin Perinatol. 2011;35(3):155–161.
- Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr. 2009;155(1):21–25.e5.
- GNI per capita, Atlas method (current US$) – United States | Data n.d.; [cited 2020 Feb 3]. Available from: https://data.worldbank.org/indicator/NY.GNP.PCAP.CD?locations=US.
- Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.
- Grosse SD, Thompson JD, Ding Y, et al. The use of economic evaluation to inform newborn screening policy decisions: The Washington State Experience: economic evaluation to inform NBS policy decisions. Milbank Q. 2016;94(2):366–391.
- Brent RJ. Cost–benefit analysis and willingness to pay. New York: Edward Elgar Publishing; 2014.
- Hutton JL, Pharoah POD. Life expectancy in severe cerebral palsy. Arch Dis Child. 2006;91(3):254–258.
- Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049.
- Economic Costs Associated with Mental Retardation, Cerebral Palsy, Hearing Loss, and Vision Impairment –- United States, 2003. n.d.; [cited 2020 Feb 3]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5303a4.htm/.
- Revised Departmental Guidance on Valuation of a Statistical Life in Economic Analysis | US Department of Transportation n.d.; [cited 2020 Feb 3]. Available from: https://www.transportation.gov/office-policy/transportation-policy/revised-departmental-guidance-on-valuation-of-a-statistical-life-in-economic-analysis.
- Bessey A, Chilcott JB, Leaviss J, et al. Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme. Orphanet J Rare Dis. 2018;13(1):179.
- Suresh GK, Clark RE. Cost-effectiveness of strategies that are intended to prevent kernicterus in newborn infants. Pediatrics. 2004;114(4):917–924.
- Weinstein MC. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–1258.
- Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935.
- Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332–342.
- Robinson LA, Hammitt JK. Valuing reductions in fatal illness risks: implications of recent research: valuing reductions in fatal illness risks. Health Econ. 2016;25(8):1039–1052.
- Vallejo-Torres L, Castilla I, Couce ML, et al. Cost-effectiveness analysis of a national newborn screening program for biotinidase deficiency. Pediatrics. 2015;136(2):e424–e432.
- Alkén J, Håkansson S, Ekéus C, et al. Rates of extreme neonatal hyperbilirubinemia and kernicterus in children and adherence to national guidelines for screening, diagnosis, and treatment in Sweden. JAMA Netw Open. 2019;2(3):e190858.
- Hokkanen L, Launes J, Michelsson K. Adult neurobehavioral outcome of hyperbilirubinemia in full term neonates—a 30 year prospective follow-up study. PeerJ. 2014;2:e294.
- Wickremasinghe AC, Kuzniewicz MW, Newman TB. Black race is not protective against hazardous bilirubin levels. J Pediatr. 2013;162(5):1068–1069. http://dx.doi.org/10.1016/j.jpeds.2012.12.092
- Rennie JM, Beer J, Upton M. Learning from claims: hyperbilirubinaemia and kernicterus. Arch Dis Child Fetal Neonatal Ed. 2019;104(2):F202–4.
- Lee J, Poitras BT. Prevalence of glucose-6-phosphate dehydrogenase deficiency, U.S. Armed Forces, May 2004–September 2018. MSMR. 2019;26(12):14–17. https://www.health.mil/Military-Health-Topics/Combat-Support/Armed-Forces-Health-Surveillance-Branch/Reports-and-Publications/∼/link.aspx?_id=534E26BD8E5D4ECC8CAA8ABA47679691&_z=z
- Algur N, Avraham I, Hammerman C, et al. Quantitative neonatal glucose-6-phosphate dehydrogenase screening: distribution, reference values, and classification by phenotype. J Pediatr. 2012;161(2):197–200.
- Nkhoma ET, Poole C, Vannappagari V, et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267–278.
- Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic Countries: a geostatistical model-based map. PLoS Med. 2012;9(11):e1001339.
- Kuzniewicz MW, Parker S-J, Schnake-Mahl A, et al. Hospital readmissions and emergency department visits in moderate preterm, late preterm, and early term infants. Clin Perinatol. 2013;40(4):753–775.
- Young PC, Korgenski K, Buchi KF. Early readmission of newborns in a large health care system. Pediatrics. 2013;131(5):e1538–e1544.
- Eggert LD, Wiedmeier SE, Wilson J, et al. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics. 2006;117(5):e855–e862.